{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:05:43Z","timestamp":1783062343425,"version":"3.54.6"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi221133-4\"><jats:title>Importance<\/jats:title><jats:p>Despite federal initiatives encouraging the enrollment of individuals from racial and ethnic minority groups in US clinical trials, no studies to date have specifically examined demographic disparities among participants in phase 1 drug development trials for patients with metastatic cancer.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221133-5\"><jats:title>Objective<\/jats:title><jats:p>To assess trends in the enrollment of patients from racial and ethnic minority groups in US phase 1 therapeutic drug trials for metastatic cancer from 2000 to 2018.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221133-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>In this cross-sectional study, ClinicalTrials.gov was queried in July 2021 to identify completed phase 1 drug trials for metastatic cancer in the US from January 1, 2000, to December 31, 2018, with published results, yielding 221 phase 1 trials with 8309 participants aged 18 years or older with metastatic solid tumors. Proportions of each racial and ethnic group of trial participants were compared with that from the North American Association of Central Cancer Registries\u2019 Cancer in North America (CiNA) database. Statistical analysis was performed from July 12, 2021, to March 15, 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221133-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>For each racial and ethnic group, the difference between trial and CiNA proportions was examined using a 2-sample test for equality of proportions with continuity correction.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221133-8\"><jats:title>Results<\/jats:title><jats:p>The 8309 phase 1 trial participants (4198 men [50.5%]; median age, 59 years) included 23 American Indian or Alaska Native participants (0.3%), 371 Asian or Pacific Islander participants (4.5%), 514 Black participants (6.2%), 401 of 5076 Hispanic or Latinx participants (7.9%), and 7154 White participants (86.1%). Industry funded 165 of the 221 trials (74.7%). White patients were overrepresented overall compared with the corresponding CiNA cohort (7154 of 8309 [86.1%] vs 4\u202f113\u202f096 of 4\u202f891\u202f486 [84.1%]; difference, 2.0 percentage points; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). There was an increase in overrepresentation of White patients from 2000 to 2011 (trials, 2780 of 3245 [85.7%]; CiNA, 2\u202f378\u202f019 of 2\u202f800\u202f711 [84.9%]; difference, 0.8 percentage points; <jats:italic>P<\/jats:italic>\u2009=\u2009.23) to 2012-2018 (trials, 4374 of 5063 [86.4%]; CiNA, 1\u202f735\u202f077 of 2\u202f090\u202f775 [82.9%]; difference, 3.5 percentage points; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and corresponding worsening representation of American Indian or Alaska Native patients (2000-2011: trials, 10 of 3245 [0.3%]; CiNA, 10\u202f905 of 2\u202f800\u202f711 [0.4%]; difference, \u22120.08 percentage points; 2012-2018: trials, 13 of 5063 [0.3%]; CiNA, 9484 of 2\u202f090\u202f775 [0.5%]; difference, \u22120.20 percentage points), Asian or Pacific Islander patients (2000-2011: trials, 121 of 3245 [3.7%]; CiNA, 75\u202f033 of 2\u202f800\u202f711 [2.7%]; difference, 1.1 percentage points; 2012-2018: trials, 151 of 5063 [3.0%]; CiNA 70\u202f535 of 2\u202f090\u202f775 [3.4%]; difference, \u22120.75 percentage points), Black patients (2000-2011: trials, 244 of 3245 [7.5%]; CiNA, 322\u202f701 of 2\u202f800\u202f711 [11.5%]; difference, \u22124.0 percentage points; 2012-2018: trials, 270 of 5063 [5.3%]; CiNA, 255\u202f625 of 2\u202f090\u202f775 [12.2%]; difference, \u22126.9 percentage points), and Hispanic or Latinx patients (2000-2011: trials, 161 of 1792 [9.0%]; CiNA, 169\u202f297 of 2\u202f800\u202f711 [6.0%]; difference, 3.0 percentage points; 2012-2018: trials, 240 of 3295 [7.3%]; CiNA, 156\u202f118 of 2\u202f090\u202f775 [7.5%]; difference, \u22120.2 percentage points). Similar disparities were observed when comparing industry-funded and academic center\u2013sponsored trials.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi221133-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cross-sectional study of participants in phase 1 clinical trials of drugs for metastatic cancer, worsening disparities were observed over time in the accrual of patients from racial and ethnic minority groups. These findings may represent widening inequalities in access to trial sites and worsening systemic biases. More efforts are needed to diversify phase 1 cancer drug trials to improve equity in access to new treatments and to ensure that safety and efficacy findings from early drug trials are generalizable across populations.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.39884","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T15:32:04Z","timestamp":1667489524000},"page":"e2239884","source":"Crossref","is-referenced-by-count":33,"title":["Participation of Patients From Racial and Ethnic Minority Groups in Phase 1 Early Cancer Drug Development Trials in the US, 2000-2018"],"prefix":"10.1001","volume":"5","author":[{"given":"Hayley","family":"Dunlop","sequence":"first","affiliation":[{"name":"The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Hunter College High School, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kurti","sequence":"additional","affiliation":[{"name":"Hunter College High School, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Deeb","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin F.","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dover","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Yerramilli","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scarlett Lin","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Chino","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Jillian","family":"Tsai","sequence":"additional","affiliation":[{"name":"Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"issue":"5","key":"zoi221133r3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0197-2456(95)00048-8","article-title":"Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993\u2014the perspective of NIH clinical trialists.","volume":"16","author":"Freedman","year":"1995","journal-title":"Control Clin Trials"},{"key":"zoi221133r4","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa060","author":"Grant","year":"2020","journal-title":"JNCI Cancer Spectr"},{"issue":"22","key":"zoi221133r5","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities.","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"10","key":"zoi221133r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018.","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi221133r7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.2014.58.2635","article-title":"American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi221133r8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"14","key":"zoi221133r9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1200\/JCO.21.01885","article-title":"Minority enrollment in phase II and III clinical trials in urologic oncology.","volume":"40","author":"Owens-Walton","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi221133r10","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1002\/cncr.v127.23","article-title":"Disparities in phase 1 cancer clinical trial enrollment.","volume":"127","author":"Perni","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"zoi221133r11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1353\/hpu.0.0323","article-title":"More than Tuskegee: understanding mistrust about research participation.","volume":"21","author":"Scharff","year":"2010","journal-title":"J Health Care Poor Underserved"},{"issue":"24","key":"zoi221133r12","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1002\/cncr.v123.24","article-title":"Improving the accrual of racial and ethnic minority patients in clinical trials: time to raise the stakes.","volume":"123","author":"Ibraheem","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"zoi221133r13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/0020731416689549","article-title":"Hospital payer and racial\/ethnic mix at private academic medical centers in Boston and New York City.","volume":"47","author":"Tikkanen","year":"2017","journal-title":"Int J Health Serv"},{"issue":"2","key":"zoi221133r14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/M19-0600","article-title":"Hospital-level care at home for acutely ill adults: a randomized controlled trial.","volume":"172","author":"Levine","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi221133r15","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jama.297.4.407","article-title":"Strategies for academic and clinician engagement in community-participatory partnered research.","volume":"297","author":"Jones","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"zoi221133r16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1200\/OP.20.00701","article-title":"Moving beyond the momentum: innovative approaches to clinical trial implementation.","volume":"17","author":"Eng","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"zoi221133r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106237","article-title":"Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications.","volume":"101","author":"Fain","year":"2021","journal-title":"Contemp Clin Trials"},{"key":"zoi221133r1","unstructured":"National Institutes of Health. National Institutes of Health Revitalization Act of 1993: subtitle B. Part 1, Sec. 131-133. Accessed August 28, 2021. https:\/\/orwh.od.nih.gov\/sites\/orwh\/files\/docs\/NIH-Revitalization-Act-1993.pdf"},{"key":"zoi221133r2","unstructured":"Federal Register. Women and minority recruitment: intervention testing. Part VIII (59 FR 11146-11151). Accessed August 28, 2021. https:\/\/grants.nih.gov\/grants\/guide\/rfa-files\/rfa-ca-96-004.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2798149\/dunlop_2022_oi_221133_1666890211.41796.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T15:32:07Z","timestamp":1667489527000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2798149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.39884","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}